The impact of drug reimbursement policy on rates of testosterone replacement therapy among older men

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Piszczek, Jolanta ^a   Mamdani, Muhammad ^a,b,e,f   Antoniou, Tony ^a,c   Juurlink, David N ^b,d   Gomes, Tara ^a,b,f  

^a UNIVERSITY OF TORONTO   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE;

AGED; ANDROGEN THERAPY; ARTICLE; CANADA; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DRUG CONTROL; DRUG FORMULARY; DRUG REIMBURSEMENT POLICY; DRUG USE; ELDERLY CARE; HEALTH CARE POLICY; HUMAN; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; REIMBURSEMENT; TIME SERIES ANALYSIS; ECONOMICS; HORMONE SUBSTITUTION; OFF LABEL DRUG USE; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; UTILIZATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; HORMONE REPLACEMENT THERAPY; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MALE; MODELS, STATISTICAL; OFF-LABEL USE; ONTARIO; TESTOSTERONE;

EID: 84904310918     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098003     Document Type: Article

References (37)

1. Liverman KT, Blazer DG, editors. (2004) Testosterone and Aging: Clinical Research Directions. Washington, DC: The National Academies Press. 1 p.
2. Handelsman DJ (2012) Pharmacoepidemiology of testosterone prescribing in Australia, 1992-2010. Med J Aust 196: 642-645.
3. Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwain JS (2013) Trends in Androgen Prescribing in the United States, 2001 to 2011. JAMA Intern Med 173: 1465-1466.
4. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, et al. (2010) Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 95: 2536-2559.
5. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, et al. (2002) Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 87: 589-598. (Pubitemid 34158223)
6. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR, et al. (2001) Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 86: 724-731. (Pubitemid 32207487)
7. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, et al. (2008) Investigation, treatment and monitoring of late-onset hypogonadism in males. Eur J Endocrinol 159: 507-514.
8. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, et al. (2005) Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol 63: 280-293. (Pubitemid 41233445)
9. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, et al. (2000) Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 85: 2670-2677. (Pubitemid 32269134)
10. Shores MM, Kivlahan DR, Sadak TI, Li EJ, Matsumoto AM (2009) A randomized, double-blind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression). J Clin Psychiatry 70: 1009-1016.
11. Kenny AM, Bellantonio S, Gruman CA, Acosta RD, Prestwood KM (2002) Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 57: 321-325.
12. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, et al. (1999) Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 84: 2647-2653. (Pubitemid 30641987)
13. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, et al. (2005) Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 90: 1502-1510. (Pubitemid 40464011)
14. Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, et al. (2010) Clinical review: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 95: 2560-2575.
15. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, et al. (2010) Adverse events associated with testosterone administration. N Engl J Med 363: 109-122.
16. Vigen R, O'Donnell CI, Baron AE, Grunwald GK, Maddox TM, et al. (2013) Association of Testosterone Therapy with Mortality, Myocardial Infarction, and Stroke in Men with Low Testosterone Levels. JAMA 301: 1829-1836.
17. Edelstein D, Dobs A, Basaria S (2006) Emerging drugs for hypogonadism. Expert Opin Emerg Drugs 11: 685-707. (Pubitemid 44735593)
18. Ontario Ministry of Health and Long-Term Care Website. Available: http://www.health.gov.on.ca/en/public/programs/drugs/programs/odb/odb.aspx. Accessed 2013 Nov 21.
19. Ministry of Health and Long Term Care Website. Ottawa (ON). Ontario Drug Benefit Formulary Update March 1, 2006. Available: http://www.health.gov.on.ca/ english/providers/program/drugs/edition-39.html. Accessed 2013 Nov 21.
20. Weir MA, Gomes T, Winquist E, Juurlink DN, Cuerden MS, et al. (2012) Effects of Funding Policy Changes and Health Warnings on the Use of Erythropoiesis-Stimulating Agents. JOP 8: 179-183.
21. Gomes T, Juurlink DN, Dhalla IA, Mailis-Gagnon A, Paterson MJ, et al. (2011) Trends in opioid use and dosing among socio-economically disadvantaged patients. Open Medicine 5: e13-e22.
22. Quail JM, Lix LM, Osman BA, Teare GF (2011) Comparing comorbidity measures for predicting mortality and hospitalization in three population-based cohorts. BMC Health Serv Res 11: 146-152.
23. Helfenstein U (1996) Box-Jenkins modelling in medical research. Stat Methods Med Res. 5: 3-22.
24. Ljung GM, Box GEP (1978) On a measure of lack of fit in time series models. Biometrika. 65: 297-303. (Pubitemid 8379490)
25. Dickey DA, Fuller WA (1979) Distribution of the estimators for autoregressive time series with a unit root. J Am Stat Assoc. 74: 427-31.
26. Mamdani M, McNeely D, Evans G, Hux J, Oh P, et al. (2007) Impact of a fluoroquinolone restriction policy in elderly population. Am J Med 120: 893-900. (Pubitemid 47451296)
27. Handelsman D (2004) Trends and regional differences in testosterone prescribing in Australia, 1991-2001. MJA 181: 419-422.
28. Kermode-Scott B (2011) Canadian regulators dismiss complaint about campaign publicising low testosterone. BMJ 343: d5501.
29. Weeks C (2012) Testosterone campaign by drug company raises concerns. The Globe and Mail. Available: http://m.theglobeandmail.com/life/health-and- fitness/testosterone-campaign-by-drug-company-raises-concerns/article595066/? service=mobile. Accessed 2013 Nov 6.
30. Eggertson L (2011) Brouhaha erupts over testosterone-testing advertising campaign. CMAJ 183: e1161-e1162.
31. Braun SR (2013) Promoting "low T": a medical writer's perspective. JAMA Intern Med 173: 1458-60.
32. Szeinbach SL, Seoane-Vazquez E, Summers KH (2012) Development of a men's Preference for Testosterone Replacement Therapy (P-TRT) instrument. Patient Prefer Adherence 6: 631-641.
33. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, et al. (1990) Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 84: 3469-3478.
34. Schoenfeld MJ, Shortridge E, Cui Z, Muram D (2013) Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy: a retrospective medical claims analysis. Sex Med 10: 1401-1409.
35. Marshall BL (2009) Rejuvenation's Return: anti-aging and re-masculinization in biomedical discourse on the "Aging Male". Medicine Studies 1: 249-265.
36. Schwartz L, Woloshin T (2013) Low "T" as in "Template"; How to Sell Disease. JAMA Intern Med 173: 1-3.
37. Handelsman D (2013) Global trends in testosterone prescribing, 2000-2011: expanding the spectrum of prescription drug misuse. MJA 199: 548-551.